Chongqing Pharscin Pharmaceutical Co (SZSE:002907) Research & Development: ¥96.9 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:002907 Chongqing Pharscin Pharmaceutical Co Ltd SZSE:002907
75 GF Score
Price ¥13.00
GF Value ¥15.38
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Chongqing Pharscin Pharmaceutical Co Research & Development?

Chongqing Pharscin Pharmaceutical Co SZSE:002907 -0.46% 75 Research & Development is ¥96.9 Mil as of Mar. 2026. GuruFocus rates SZSE:002907 with a GF Score™ of 75/100 and a GF Value™ of ¥15.38 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Chongqing Pharscin Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was ¥19.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥96.9 Mil.

Chongqing Pharscin Pharmaceutical Co  (SZSE:002907) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chongqing Pharscin Pharmaceutical Co Research & Development Related Terms

Chongqing Pharscin Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Chongqing Pharscin Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chongqing Pharscin Pharmaceutical Co Research & Development Chart

Chongqing Pharscin Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.72 58.82 78.12 59.13 89.76

Chongqing Pharscin Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.31 24.74 22.20 30.52 19.49
SZSE:002907
75GF Score
Chongqing Pharscin Pharmaceutical Co Ltd SZSE:002907
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chongqing Pharscin Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥96.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥96.9 Mil mean?
Chongqing Pharscin Pharmaceutical Co (SZSE:002907) has a Research & Development of ¥96.9 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Chongqing Pharscin Pharmaceutical Co and its competitors.
Is Chongqing Pharscin Pharmaceutical Co's Research & Development too high?
Chongqing Pharscin Pharmaceutical Co's current Research & Development is ¥96.9 Mil. Overall, Chongqing Pharscin Pharmaceutical Co has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chongqing Pharscin Pharmaceutical Co's Research & Development compare to ZTS?
Chongqing Pharscin Pharmaceutical Co's Research & Development of ¥96.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chongqing Pharscin Pharmaceutical Co and its competitors. Chongqing Pharscin Pharmaceutical Co's current Research & Development is ¥96.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Pharscin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Pharscin Pharmaceutical Co (SZSE:002907) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.38, compared to a current price of ¥13.00 — trading 15.5% below its estimated fair value. The current Research & Development is ¥96.9 Mil. Chongqing Pharscin Pharmaceutical Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chongqing Pharscin Pharmaceutical Co (SZSE:002907), the current Research & Development is ¥96.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chongqing Pharscin Pharmaceutical Co (SZSE:002907) Overvalued in 2026?

Based on GuruFocus' analysis, Chongqing Pharscin Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥13.00 is trading 15.5% below its estimated GF Value™ of ¥15.38. GuruFocus considers Chongqing Pharscin Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SZSE:002907:

  • Research & Development: ¥96.9 Mil
  • GF Value™: ¥15.38 vs. price of ¥13.00 (15.5% below fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the SZSE:002907 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chongqing Pharscin Pharmaceutical Co Business Description

Address No. 89, Middle Section of Huangshan Avenue, Yubei District, Chongqing, CHN, 401120
Chongqing Pharscin Pharmaceutical Co Ltd is a China-based pharmaceutical research and development company. It produces and sells medicines in form of tablets, powders, granules, hard capsules, soft capsules, powder injection, freeze-dried powder injection, small volume injection, raw material synthesis and botanical extracts. It operates internationally.
75GF Score

Get the complete analysis for SZSE:002907

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥13.00
Price
¥15.38
GF Value